Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of (S)-CE-123 and Modafiendz — mechanism, side effects, legal status, and pricing.
(S)-CE-123 is a non-peptide small molecule belonging to the diphenylmethyl-sulfinyl-thiazole chemotype, structurally related to modafinil. It acts as an atypical, non-releasing dopamine transporter (DAT) inhibitor—blocking dopamine reuptake without triggering amphetamine-like transporter-mediated release. No human clinical data exist; all pharmacology, behavioral, and pharmacokinetic findings are preclinical (rodent in vivo and human-liver-microsome/HEK293-cell in vitro). The compound is not individually named on WADA's current Prohibited List, though modafinil (the parent compound) is a named S6 stimulant; no authoritative WADA ruling specific to CE-123 was found.
Modafiendz is a non-peptide diphenylmethylsulfinylacetamide, specifically an N-methylated, bis(4-fluoro)-ring-substituted analog of modafinil. It is an unapproved research/designer chemical with no marketing authorization in any jurisdiction and no validated human dose. Its closest structural relatives, flmodafinil (CRL-40,940) and fladrafinil (CRL-40,941), are explicitly named as WADA-prohibited S6 stimulants on the 2026 list; Modafiendz itself is not explicitly named but may fall under WADA's generic “similar structure or effect” clause. No human pharmacokinetic, safety, or efficacy studies have been published.
(S)-CE-123
Modafiendz
Category
Legal Status
Mechanism
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
(S)-CE-123
No pricing data yet.
Check (S)-CE-123 prices →Modafiendz
No pricing data yet.
Check Modafiendz prices →COA corpus from Disclosed Labs — independently tested batches only.
(S)-CE-123
2
COAs
99.9%
Avg purity
2
Labs
Modafiendz
2
COAs
99.5%
Avg purity
2
Labs
No human data exist for (S)-CE-123. No registered ClinicalTrials.gov trials or DrugBank entries were found, and the primary source explicitly states that no human data are available. All pharmacology and behavioral data are preclinical. In rats, (S)-CE-123 at 24.0 mg/kg i.p. partially reversed tetrabenazine-induced deficits in effort-based lever pressing, increased progressive-ratio responding, and raised extracellular dopamine in the nucleus accumbens core. At 0.3–1.0 mg/kg i.p., CE-123 improved extra-dimensional set-shifting in an attentional task without the impulsivity-increasing effects observed with R-modafinil at 10 mg/kg. Daily dosing improved spatial memory acquisition and retrieval in a hole-board task and ameliorated maternal-separation-induced spatial learning deficits in adolescent rats, with sex-dependent effects. Pharmacokinetic studies in rats and human liver microsomes show that S-CE-123 achieves ~5-fold greater unbound brain penetration (Kp,uu,brain = 0.5) than R-modafinil but is metabolized 9.3-fold faster in human liver microsomes (t₁/₂ 39 min vs. 364 min).
Key references
No human data exists. No ClinicalTrials.gov record, no DrugBank entry, and no INN was found; NCATS Inxight Drugs classifies it only as “Other (designer drug),” racemic, with no approval year. Only two PubMed-indexed publications reference this compound, both analytical/forensic chemistry papers: one validated an LC-HRMS method to screen dietary supplements for modafinil analogs (adrafinil, not Modafiendz, was confirmed present in tested products), and one analyzed heat-induced thermal degradation during GC-MS (relevant to forensic identification). No preclinical pharmacology, toxicology, or efficacy studies in animals have been published.
(S)-CE-123 and Modafiendz are both in the Cognitive category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Key references
Disclosed Labs